Skandinaviska Enskilda Banken AB publ Has $3.65 Million Holdings in DaVita Inc. (NYSE:DVA)

Skandinaviska Enskilda Banken AB publ trimmed its stake in shares of DaVita Inc. (NYSE:DVA) by 43.3% during the second quarter, HoldingsChannel reports. The fund owned 26,306 shares of the company’s stock after selling 20,100 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in DaVita were worth $3,645,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of DaVita by 2.4% in the 4th quarter. Vanguard Group Inc. now owns 6,320,740 shares of the company’s stock valued at $662,161,000 after purchasing an additional 145,711 shares during the period. Gates Capital Management Inc. raised its position in DaVita by 3.1% in the 4th quarter. Gates Capital Management Inc. now owns 905,830 shares of the company’s stock valued at $94,895,000 after buying an additional 27,660 shares during the last quarter. 8 Knots Management LLC acquired a new stake in DaVita in the 4th quarter valued at approximately $89,504,000. Allianz Asset Management GmbH lifted its stake in DaVita by 63.9% in the 4th quarter. Allianz Asset Management GmbH now owns 548,642 shares of the company’s stock valued at $57,476,000 after acquiring an additional 213,992 shares in the last quarter. Finally, Doma Perpetual Capital Management LLC acquired a new position in DaVita during the 4th quarter worth approximately $53,076,000. 90.12% of the stock is owned by institutional investors.

Insider Buying and Selling at DaVita

In other news, CEO Javier Rodriguez sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the transaction, the chief executive officer now owns 837,835 shares of the company’s stock, valued at $138,284,666.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the company’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the transaction, the chief executive officer now directly owns 837,835 shares of the company’s stock, valued at approximately $138,284,666.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Joel Ackerman sold 64,029 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total value of $9,928,336.74. Following the transaction, the chief financial officer now owns 111,481 shares in the company, valued at approximately $17,286,243.86. The disclosure for this sale can be found here. Insiders have sold a total of 173,482 shares of company stock valued at $27,387,069 in the last three months. 2.00% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on DVA. Truist Financial boosted their price objective on shares of DaVita from $150.00 to $165.00 and gave the stock a “hold” rating in a research report on Tuesday, August 20th. Bank of America increased their price objective on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 7th. UBS Group lifted their target price on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. Finally, TD Cowen boosted their price target on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, DaVita currently has a consensus rating of “Hold” and a consensus target price of $157.00.

DaVita Stock Performance

Shares of NYSE DVA opened at $164.00 on Monday. DaVita Inc. has a 12 month low of $71.51 and a 12 month high of $166.04. The stock has a 50 day moving average of $147.64 and a 200-day moving average of $141.23. The company has a current ratio of 1.16, a quick ratio of 1.12 and a debt-to-equity ratio of 9.94. The company has a market capitalization of $14.38 billion, a P/E ratio of 18.64, a P/E/G ratio of 0.95 and a beta of 0.87.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.47 by $0.12. The firm had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The company’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the company earned $2.08 earnings per share. As a group, equities research analysts predict that DaVita Inc. will post 9.99 EPS for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.